DE1129483B - Process for the preparation of therapeutically active steroid compounds - Google Patents

Process for the preparation of therapeutically active steroid compounds

Info

Publication number
DE1129483B
DE1129483B DEU6462A DEU0006462A DE1129483B DE 1129483 B DE1129483 B DE 1129483B DE U6462 A DEU6462 A DE U6462A DE U0006462 A DEU0006462 A DE U0006462A DE 1129483 B DE1129483 B DE 1129483B
Authority
DE
Germany
Prior art keywords
preparation
therapeutically active
steroid compounds
active steroid
dioxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEU6462A
Other languages
German (de)
Inventor
Frank Harris Lincoln Jun
William Paul Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of DE1129483B publication Critical patent/DE1129483B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)

Description

Verfahren zur Herstellung therapeutisch wirksamer Steroidverbindungen Gegenstand der Erfindung ist ein Verfahren zur Herstellung von therapeutisch wirksamen Steroidverbindungen der allgemeinen Formel in der R = H, OH oder Ketosauerstoff und X -- Wasserstoff, Fluor oder Chlor bedeutet und sich in l(2)-Stellung eine weitere Doppelbindung befinden kann. Sie werden nach folgendem Reaktionsschema erhalten: Die neuen, erfindungsgemäß herstellbaren 16x-Methylsteroldverbindu.ngen, insbesondere ihre 9a-Chlor-und 9cc-Fluorderivate, besitzen bei geringen Nebenerscheinungen, wie Magen-Darm-Störungen, Salzretention iin Gewebe, Ödembildung, die bei ähnlichen physiologisch wirksamen Steroiden ohne 16ständige Methylgruppe häufig in unerwünschtem Grade auftreten, ausgezeichnete entzündungswidrige Wirkung. Sie eignen sich zur Behandlung von verschiedenen Entzündungszuständen der Haut, Augen, Atmungsorgane, Knochen und inneren Organe des tierischen Organismus, die durch Bakterien- oder Virusinfektionen, Kontaktdermatitis und allergische Reaktionen verursacht werden. Zu diesem Zweck kömied #i#-,gegebenenfalls mit bekannten Antibiotika, wie Penicillin, Neomycin, Tetracyclin, Chloromycetin und Novobiocin, verschiedenen Salbengrundlagen zugemischt und in die Form von Cremes, Lösungen, Lotionen, Suspensionen und Sprays gebracht werden.Process for the preparation of therapeutically active steroid compounds The invention relates to a process for the preparation of therapeutically active steroid compounds of the general formula in which R = H, O H or keto oxygen and X - is hydrogen, fluorine or chlorine and there may be another double bond in the l (2) position. You will receive according to the following reaction scheme: The new 16x-methylsterol compounds that can be prepared according to the invention, in particular their 9a-chloro and 9cc-fluorine derivatives, have minor side effects such as gastrointestinal disorders, salt retention in tissue, and edema, which is common in similar physiologically active steroids without a 16-methyl group occur in an undesirable degree, excellent anti-inflammatory effect. They are suitable for the treatment of various inflammatory conditions of the skin, eyes, respiratory organs, bones and internal organs of the animal organism, which are caused by bacterial or viral infections, contact dermatitis and allergic reactions. For this purpose, different ointment bases can be mixed in with known antibiotics such as penicillin, neomycin, tetracycline, chloromycetin and novobiocin and made into the form of creams, solutions, lotions, suspensions and sprays.

Zur Durchführung des erfindungsgemäßen Verfahrens werden das Ilß,17,y-Dioxy-16a-methvl-21-jod-4-pregnen (bzw. -1,4-preÜädien).#'3,2Ö'-dion bzw. dessen 9oc-Halogenderivate in---an sich bekannter Weise in einem wäßrigen organischen- Lösungsmittelgemisch mit einem Reduktionsmittel, z. B.: Natriumthiosulfat, Natriumbisulfit, Kaliuihbisulfit o'd * - dgl., behandelt. Anschließend kann die 1 Iß-ständige Hydroxylgruppe mit Chromsäureanhydrid, N-Bromacetatamid oder N-Bromsuccinimid zur Ketogruppe oxydiert werden.To carry out the process according to the invention, ILß, 17, γ-dioxy-16a-methvl-21-iodine-4-pregnen (or -1,4-preÜadien). # '3,2Ö'-dione or its 9oc- Halogen derivatives in a manner known per se in an aqueous organic solvent mixture with a reducing agent, e.g. B .: Sodium thiosulfate, sodium bisulfite, Kaliuihbisulfit o'd * - like. Treated. Subsequently, the 1-position hydroxyl group with chromic anhydride Eat, N-Bromacetatamid or N-bromosuccinimide can be oxidized to the keto group.

Das folgende Beispiel erläutert das erfindungsgemäße. Verfahren. Beispiel 1 Iß, 17,x - Dioxy - 16x - methyl - 4 - pregnen -,3,20 - dion 150mg Ilß,17x-Dioxy-16x-meihyl-21-jod-4-pregnen-3,20-dion werden mit 5ccm Essigsäure aufgeschlämmt und 45 Minuten gerührt. Dann wird eine wäßrige Lösung von 250 mg Natriumthiosulfat Pentahydrat zugesetzt, worauf die Jodfarbe verschwindet. Es werden noch 50 ccm Wasser zugesetzt, worauf das Gemisch dreimal mit je 25 ccm Methylenehlorid extrahiert wird. Die Methylenchloridextrakte werden vereinigt und mit Wasser und kalter Natriumbicarbonatlösung gewaschen, bis die gesamte Essigsäure neutralisiert ist. Nach dem Trocknen über wasserfreiem Natriumsulfat wird die Lösung auf etwa 15 ccm eingeengt und über 10 g Magnesiumsilikat, bekannt unter dem Handelsnamen »Florisü«, chromatographiert. Die Säule wird mit Hexankohlenwasserstoffen, die steigende Mengen Aceton enthalten, entwickelt. Man erhält im wesentlichen reines lIP,17cc-Dioxy-16x-methyl-4-pregnen-3,20-dion; F. = 190'C; weiterer Schmelzpunkt nach Verfestigung 204 bis 211'C; Infrarotabsorption bei 3480, 3320, 1688, 1659, 1650, 1630 und 1615 cm-'; [OCID = 101' (Chloroform). Analyse für C.11H1104: Berechnet ... C 73,30, H 8,95; gefunden ... C 73,42, H 9,08. Die erhaltene Verbindung kann nachfolgend in das 11-Ketoderivat übergeführt werden.The following example illustrates the invention. Procedure. Example 1 Iß, 17, x - Dioxy - 16x - methyl - 4 - pregnen -, 3.20 - dione 150mg Ilß, 17x-dioxy-16x-methyl-21-iodo-4-pregnen-3,20-dione are with Slurried 5ccm acetic acid and stirred for 45 minutes. An aqueous solution of 250 mg of sodium thiosulfate pentahydrate is then added, whereupon the iodine color disappears. A further 50 cc of water are added, whereupon the mixture is extracted three times with 25 cc of methylene chloride each time. The methylene chloride extracts are combined and washed with water and cold sodium bicarbonate solution until all of the acetic acid is neutralized. After drying over anhydrous sodium sulfate, the solution is concentrated to about 15 cc and chromatographed over 10 g of magnesium silicate, known under the trade name "Florisu". The column is developed with hexane hydrocarbons containing increasing amounts of acetone. Essentially pure IIP, 17cc-dioxy-16x-methyl-4-pregnen-3,20-dione is obtained; M.p. = 190'C; further melting point after solidification 204 to 211 ° C; Infrared absorption at 3480, 3320, 1688, 1659, 1650, 1630 and 1615 cm- '; [OCID = 101 ' (chloroform). Analysis for C.11H1104: Calculated ... C 73.30, H 8.95; Found ... C 73.42, H 9.08. The compound obtained can subsequently be converted into the 11-keto derivative.

In gleicher Weise erhielt man aus llß,17x-Dioxy-16x - methyl - 21 -jod - 1,4 - pregnadien - 3,20 - dion das llß ' 17,x-Dioxy-16,x-methyl-1,4-pregnadien-3,20-dion; F. = 205 bis 212' C; Infrarotabsorption bei 3530, 3330, 3285, 1690, 1655, 1613, 1600, 1218, 1183, 1138 und 1115 cm-'; HD = 44' (Chloroform).' Analyse für C22H3004: Berechnet ... C 73,71, H 8,44; gefunden ... C 73,8 1, H 8,8 1. 9ox-Fluor-Ilfl,17oc-dioxy-16oc-methyl-21-jod-1,4-pre- gnadien-3,20-dion ergab 9a-Fluor-llp,17,x-dioxy- 16x-methyl-1,4-pregnadien-3,20-dion; F.=257 bis h _ 2590-C-,---ÄMA'akxo- 0'1 ' 239 m#t (s = 15300); Infrarotab- serption bei 3400, - 1704, 1665, 1625, 1607, 1190, 1125 und 1064 cm-'. Analyse für CI2H2104: Berechnet ... C 70,19, H 7,76, F 5,05; gefunden ... C 69,83, H 7,89, F 5,15. 21 iodo - - 1.4 - In the same manner was obtained from LLSs, 17x-16x dioxy - methyl pregnadiene - 3,20 - dione, the LLSs' 17, x-dioxy-16, x-methyl-1,4- pregnadien-3,20-dione; F. = 205 to 212 ° C; Infrared absorption at 3530, 3330, 3285, 1690, 1655, 1613, 1600, 1218, 1183, 1138 and 1115 cm- '; HD = 44 '(chloroform).' Analysis for C22H3004: Calculated ... C 73.71, H 8.44; found ... C 73.8 1, H 8.8 1. 9ox-Fluor-Ilfl, 17oc-dioxy-16oc-methyl-21-iodine-1,4-pre- Gnadien-3,20-dione yielded 9a-fluoro-llp, 17, x-dioxy- 16x-methyl-1,4-pregnadiene-3,20-dione; F. = 257 to h _ 2590-C-, --- ÄMA'akxo- 0'1 '239 m # t (s = 15300); Infrared serption at 3400, - 1704, 1665, 1625, 1607, 1190, 1125 and 1064 cm- '. Analysis for CI2H2104: Calculated ... C 70.19, H 7.76, F 5.05; Found ... C 69.83, H 7.89, F 5.15.

Claims (2)

PATENTANSPRÜCHE: 1. Verfahren zur Herstellung therapeutisch wirksame,r Steroidverbindungender allgemeinen Formel in der X Wasserstoff, Fluor oder Chlor, R =B,# 0 Hoder Ketosauerstöff bedeutet und.sich in'l (2)-StellÜng-eine zusätzliche Doppelbindung befinden kann, dadurch ge]#ennzeiklinet, -daß man eine Verbindung der allgemeinen Formel in der X die angegebene Bedeutung hat, oder deren A '-Analoges in an sich bekannter Weise mit einem Reduktionsmittel behandelt und gegebenenfalls die llß-ständige Hydroxylgruppe oxydiert. PATENT CLAIMS: 1. Process for the preparation of therapeutically active steroid compounds of the general formula in which X is hydrogen, fluorine or chlorine, R = B, # 0 is H or keto oxygen and in'l (2) position there can be an additional double bond, which means that a compound of the general formula is used in which X has the meaning given, or its A 'analog is treated in a manner known per se with a reducing agent and, if appropriate, the 11β-hydroxyl group is oxidized. 2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man als Reduktionsmittel Natriumthiosulfat verwendet.2. The method according to claim 1, characterized in that sodium thiosulfate is used as the reducing agent.
DEU6462A 1958-09-08 1959-08-29 Process for the preparation of therapeutically active steroid compounds Pending DE1129483B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1129483XA 1958-09-08 1958-09-08

Publications (1)

Publication Number Publication Date
DE1129483B true DE1129483B (en) 1962-05-17

Family

ID=22346717

Family Applications (1)

Application Number Title Priority Date Filing Date
DEU6462A Pending DE1129483B (en) 1958-09-08 1959-08-29 Process for the preparation of therapeutically active steroid compounds

Country Status (1)

Country Link
DE (1) DE1129483B (en)

Similar Documents

Publication Publication Date Title
DE2437847C3 (en) 16?, 17? -Cyclopentylidenedioxy-9α-fluorine-11β, 21-dihydroxy-1,4-pregnadiene-3,20-dione-21-acetate, process for its preparation and pharmaceutical agent containing it
DE1239307B (en) Process for the preparation of therapeutically active steroid compounds
DE1643036A1 (en) New 11ss halogen steroids
DE2047105C3 (en) 17-chloro steroids and process for their preparation
DE2607418A1 (en) TERPENOIDESTERS OF STEROIDS, THE PROCESS FOR THEIR MANUFACTURING AND PREPARATIONS CONTAINING THEM
DE3336292C2 (en)
DE1129483B (en) Process for the preparation of therapeutically active steroid compounds
CH504423A (en) 9alpha 11beta-dihalo-16alpha-alkyl-1 4-pregnadien
DE2318767C3 (en) Triamcinolone derivative, process for its preparation and medicinal product containing it
DE2852055C2 (en)
DE1124037B (en) Process for the preparation of therapeutically active steroid compounds
DE2709078C2 (en) Novel halogen derivatives of the 16α-methylpregnane series, processes for their preparation and pharmaceutical compositions containing them
DE2904614A1 (en) CHLORMETHYL-17 ALPHA -ACETOXY- 9 ALPHA -FLUOR-11 BETA -HYDROXY-16 BETA -METHYL-3-OXOANDROSTA-1,4-DIEN-17 BETA -CARBOXYLATE, METHOD FOR THE PRODUCTION THEREOF AND THE PRODUCT CONTAINED THEREOF
DE1193941B (en) Process for the preparation of therapeutically effective 16beta-alkyl-9alpha-fluoro-11beta, 17alpha, 21-trioxy-4-pregnen-3, 20-dione-21-acylates or the corresponding 2
AT231618B (en) Process for the preparation of 1, 4, 9 (11) -unsaturated compounds of the pregnane series
DE1037452B (en) Process for the preparation of 6-halo-4-pregnene-11ª‰, 17ª‡, 21-triol-3, 20-dione and 6-halo-4-pregnene-17ª‡, 21-diol-3, 11, 20- trions and their 21-acylates
DE1768673C (en) 6 alpha, 9 alpha-difluoroprednisolone-17,21-diester
DE1668857C (en) 6 alpha, 9 alpha difluorprednisolone 17 valerate 21 acetate
DE1668859C (en) 6 alpha, 9 alpha difluorohydrocortisone or prednisolone 17 valerate
DE2742982C2 (en) 9-chlorprednisolone derivatives, process for their production and pharmaceutical preparation containing them
DE1768673B1 (en) 6alpha, 9alpha-difluorprednisolone-17,21-diester
DE1150076B (en) Process for the production of therapeutically effective 6ª ‡ -fluoromethyl steroids
DE1027668B (en) Method of making steroids
DE1047199B (en) Process for the preparation of a 17 ‡, 21-dioxy or 17 ‡ -oxy-21-acyloxy-1,4-pregnadiene-3,20-dione
CH495969A (en) Delta1 4-16alpha-methyl-steroids